stoxline Quote Chart Rank Option Currency Glossary
  
Deciphera Pharmaceuticals, Inc. (DCPH)
14.67  0.44 (3.09%)    04-19 16:00
Open: 14.17
High: 14.69
Volume: 373,106
  
Pre. Close: 14.23
Low: 14.05
Market Cap: 1,185(M)
Technical analysis
2024-04-19 5:08:47 PM
Short term     
Mid term     
Targets 6-month :  18.17 1-year :  19.26
Resists First :  15.55 Second :  16.48
Pivot price 15.12
Supports First :  14.05 Second :  11.68
MAs MA(5) :  14.67 MA(20) :  15.15
MA(100) :  15.2 MA(250) :  14.06
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  15.2 D(3) :  14.8
RSI RSI(14): 42.6
52-week High :  17.72 Low :  9.89
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ DCPH ] has closed above bottom band by 21.8%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.72 - 14.82 14.82 - 14.91
Low: 13.81 - 13.94 13.94 - 14.05
Close: 14.48 - 14.67 14.67 - 14.85
Company Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Headline News

Wed, 17 Apr 2024
Investors Who Bought Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Three Years Ago Are Now Up 97% - Yahoo Movies Canada

Wed, 17 Apr 2024
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Up 7.3% in March - MarketBeat

Tue, 09 Apr 2024
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum - Business Wire

Thu, 28 Mar 2024
Where Will Deciphera Pharmaceuticals Inc (DCPH) Stock Go Next After It Has Gained 1.68% in a Week? - InvestorsObserver

Wed, 27 Mar 2024
DCPH Stock Quote Price and Forecast - CNN

Thu, 07 Mar 2024
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 81 (M)
Shares Float 41 (M)
Held by Insiders 30.4 (%)
Held by Institutions 73.4 (%)
Shares Short 6,060 (K)
Shares Short P.Month 5,510 (K)
Stock Financials
EPS -2.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.36
Profit Margin -119.4 %
Operating Margin -106.1 %
Return on Assets (ttm) -28.5 %
Return on Equity (ttm) -56.3 %
Qtrly Rev. Growth 32.9 %
Gross Profit (p.s.) 0
Sales Per Share 2.02
EBITDA (p.s.) -2.59
Qtrly Earnings Growth 0 %
Operating Cash Flow -147 (M)
Levered Free Cash Flow -73 (M)
Stock Valuations
PE Ratio -6.41
PEG Ratio -0.4
Price to Book value 3.36
Price to Sales 7.25
Price to Cash Flow -8.09
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android